Back to Newsroom

Athersys Reports Alignment of Key Regulators for Pivotal Registration Study in Stroke

CLEVELAND, Aug. 07, 2017 (GLOBE NEWSWIRE) — Athersys, Inc. (Nasdaq:ATHX) today announced that the design of its Phase 3 clinical study treating ischemic stroke with its proprietary MultiStem® cell therapy product (the “MASTERS-2” study) has received a Final Scientific Advice positive opinion from the European Medicines Agency (“EMA”).  This represents EMA’s opinion that, upon success, the study should be sufficient to warrant approval for commercialization, which is in line with the U.S. Special Protocol Assessment and Fast Track Designation.